Javascript must be enabled to continue!
The Higher Isoform of G6PD Directly Binds to the Myocardin Promoter and Regulates its Expression in Vascular Smooth Muscle Cells
View through CrossRef
Smooth muscle cell (SMC) plasticity is regulated by several
transcription factors, such as Serum response factor (Srf) and co-activator
Myocardin (MYOCD) and krüppel-like factors 4 and 5 (KLF4 and KLF5).
SRF-MYOCD invokes the expression of SMC-restricted genes and controls
differentiated phenotype of the vascular smooth muscle cells (VSMCs).
Recently we demonstrated that the novel high molecular weight (HMW) isoform
of glucose-6-phosphate dehydrogenase (G6PD 545 )
suppresses the transcription of Myocardin ( Myocd ) gene, in VSMCs. However,
the underlying mechanism through which G6PD 545
regulates the transcription of the Myocd gene is unclear. We hypothesized
that G6PD 545 directly binds to the Myocd promoter and
transcriptionally suppresses its gene expression. First, we subjected VSMCs
to fractionation studies using ultracentrifugation and observed the presence
of the enzymatically active G6PD 545 protein in the
nuclear fraction. Next, we performed CHIP analysis in human coronary artery
smooth muscle cells using anti-G6PD antibody and conducted PCR to amplify 3
fragments within the 700 bp of the Myocd promoter, upstream of the TSS. We
found that G6PD 545 was bound to a DNA fragment between
-166 to +57 bp of the Myocd promoter, upstream of TSS, based on the amplicon
obtained in the PCR reaction. Furthermore, we synthesized 4 Biotin-labeled
oligos encompassing the region -166 to +57 of the Myocd promoter and
conducted EMSA assays to narrow down the G6PD 545
binding site on the Myocd promoter. We observed that Oligo#2 was robustly
bound by G6PD 545 and harbored a SP1 like DNA
recognition sequence –“GGGGAGGCG”. Deletion of this 9-mer from Oligo#2
resulted in the complete inhibition of G6PD 545 binding
to the Oligo#2, suggesting that G6PD 545 recognized a
specific/cognate DNA binding sequence on the Myocd promoter similar to that
observed in other transcription factors. Furthermore, we cloned the 700 bp
Myocd promoter in the pGL3-Basic Luciferase vector and performed the Dual
Luciferase assays ± G6PD 545 -wild type (G6PD
hi -wt) protein, that was cloned in the
pDsRed-Express-N1 Vector. We found that co-transfection of the Myocd
promoter with G6PD 545 -wt, in HEK293T17 cells,
significantly decreased the Myocd promoter activity, suggesting that G6PD
545 -wt may be functioning as a repressor of the
Myocd promoter activity. Moreover, enzymatically inactive G6PD
545 mutant was did not suppress Myocd promoter
activity, suggesting that the DNA binding activity of G6PD
545 is independent of its enzymatic activity. Taken
together, this data indicates that G6PD 545 may
function as a novel transcription factor and regulate the expression of
proteins involved in the differentiation of VSMCs.
NHLBI R01HL166546 and R01HL132574
This abstract was presented at the American Physiology Summit 2025 and
is only available in HTML format. There is no downloadable file or PDF
version. The Physiology editorial board was not involved in the peer review
process.
Title: The Higher Isoform of G6PD Directly Binds to the Myocardin Promoter and
Regulates its Expression in Vascular Smooth Muscle Cells
Description:
Smooth muscle cell (SMC) plasticity is regulated by several
transcription factors, such as Serum response factor (Srf) and co-activator
Myocardin (MYOCD) and krüppel-like factors 4 and 5 (KLF4 and KLF5).
SRF-MYOCD invokes the expression of SMC-restricted genes and controls
differentiated phenotype of the vascular smooth muscle cells (VSMCs).
Recently we demonstrated that the novel high molecular weight (HMW) isoform
of glucose-6-phosphate dehydrogenase (G6PD 545 )
suppresses the transcription of Myocardin ( Myocd ) gene, in VSMCs.
However,
the underlying mechanism through which G6PD 545
regulates the transcription of the Myocd gene is unclear.
We hypothesized
that G6PD 545 directly binds to the Myocd promoter and
transcriptionally suppresses its gene expression.
First, we subjected VSMCs
to fractionation studies using ultracentrifugation and observed the presence
of the enzymatically active G6PD 545 protein in the
nuclear fraction.
Next, we performed CHIP analysis in human coronary artery
smooth muscle cells using anti-G6PD antibody and conducted PCR to amplify 3
fragments within the 700 bp of the Myocd promoter, upstream of the TSS.
We
found that G6PD 545 was bound to a DNA fragment between
-166 to +57 bp of the Myocd promoter, upstream of TSS, based on the amplicon
obtained in the PCR reaction.
Furthermore, we synthesized 4 Biotin-labeled
oligos encompassing the region -166 to +57 of the Myocd promoter and
conducted EMSA assays to narrow down the G6PD 545
binding site on the Myocd promoter.
We observed that Oligo#2 was robustly
bound by G6PD 545 and harbored a SP1 like DNA
recognition sequence –“GGGGAGGCG”.
Deletion of this 9-mer from Oligo#2
resulted in the complete inhibition of G6PD 545 binding
to the Oligo#2, suggesting that G6PD 545 recognized a
specific/cognate DNA binding sequence on the Myocd promoter similar to that
observed in other transcription factors.
Furthermore, we cloned the 700 bp
Myocd promoter in the pGL3-Basic Luciferase vector and performed the Dual
Luciferase assays ± G6PD 545 -wild type (G6PD
hi -wt) protein, that was cloned in the
pDsRed-Express-N1 Vector.
We found that co-transfection of the Myocd
promoter with G6PD 545 -wt, in HEK293T17 cells,
significantly decreased the Myocd promoter activity, suggesting that G6PD
545 -wt may be functioning as a repressor of the
Myocd promoter activity.
Moreover, enzymatically inactive G6PD
545 mutant was did not suppress Myocd promoter
activity, suggesting that the DNA binding activity of G6PD
545 is independent of its enzymatic activity.
Taken
together, this data indicates that G6PD 545 may
function as a novel transcription factor and regulate the expression of
proteins involved in the differentiation of VSMCs.
NHLBI R01HL166546 and R01HL132574
This abstract was presented at the American Physiology Summit 2025 and
is only available in HTML format.
There is no downloadable file or PDF
version.
The Physiology editorial board was not involved in the peer review
process.
Related Results
Opposite roles of myocardin and atrogin‐1 in L6 myoblast differentiation
Opposite roles of myocardin and atrogin‐1 in L6 myoblast differentiation
AbstractL6 rat myoblasts undergo differentiation and myotube formation when cultured in medium containing a low‐concentration of serum, but the underlying mechanism is not well und...
Prevalence and distribution of glucose-6-phosphate dehydrogenase (G6PD) variants in Thai and Burmese populations in malaria endemic areas of Thailand
Prevalence and distribution of glucose-6-phosphate dehydrogenase (G6PD) variants in Thai and Burmese populations in malaria endemic areas of Thailand
AbstractBackgroundG6PD deficiency is common in malaria endemic regions and is estimated to affect more than 400 million people worldwide. Treatment of malaria patients with the ant...
HDAC Expression and Activity in Vascular Smooth Muscle Cells is Regulated by Glucose‐6‐Phosphate Dehydrogenase
HDAC Expression and Activity in Vascular Smooth Muscle Cells is Regulated by Glucose‐6‐Phosphate Dehydrogenase
Glucose‐6‐phosphate dehydrogenase (G6PD), a key enzyme in the glucose metabolism, regulates vascular smooth muscle cell (VSMC) phenotype and function. In proteomic analysis, we dis...
Poster 247: Muscle ERRγ Overexpression Mitigates the Muscle Atrophy after ACL injury
Poster 247: Muscle ERRγ Overexpression Mitigates the Muscle Atrophy after ACL injury
Objectives:
Anterior cruciate ligament (ACL) reconstruction is the 6th most common orthopedic procedure performed in the United States (1,2). There is substanti...
Glucose-6-phosphate Dehydrogenase (G6PD): the Role in Tumor Progression and Immunotherapy
Glucose-6-phosphate Dehydrogenase (G6PD): the Role in Tumor Progression and Immunotherapy
Abstract
Background: Numerous studies have shown that glucose-6-phosphate dehydrogenase (G6PD) is a tumor-promoting factor in a variety of malignancies. However, it is not ...
PREVALENCE AND MOLECULAR CHARACTERIZATION OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENCY IN FEMALES FROM PREVIOUSLY MALARIA ENDEMIC REGIONS IN NORTHEASTERN THAILAND AND IDENTIFICATION OF A NOVEL G6PD VARIANT
PREVALENCE AND MOLECULAR CHARACTERIZATION OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENCY IN FEMALES FROM PREVIOUSLY MALARIA ENDEMIC REGIONS IN NORTHEASTERN THAILAND AND IDENTIFICATION OF A NOVEL G6PD VARIANT
Introduction: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common X-linked enzymopathy, highly prevalent in areas where malaria is or has been endemic. Prevalenc...
Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers
Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers
Tafenoquine is an 8-aminoquinoline under investigation for the prevention of relapse in
Plasmodium vivax
malaria. This open-label, dose-esca...
Management of glucose 6-phosphate dehydrogenase (G6PD) deficient patients undergoing open-heart surgery
Management of glucose 6-phosphate dehydrogenase (G6PD) deficient patients undergoing open-heart surgery
Background: There are scarce studies on the management of glucose 6-phosphate dehydrogenase (G6PD) deficient patients during cardiac surgery. The purposes of this retrospective stu...

